Zinc chelation: a metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance

[1]  V. Adam,et al.  The Role of Metallothionein in Oxidative Stress , 2013, International journal of molecular sciences.

[2]  Vojtech Adam,et al.  Metallothioneins and zinc in cancer diagnosis and therapy , 2012, Drug metabolism reviews.

[3]  J. Błasiak,et al.  Zinc differentially modulates DNA damage induced by anthracyclines in normal and cancer cells. , 2012, Experimental oncology.

[4]  V. Adam,et al.  From amino acids to proteins as targets for metal-based drugs. , 2012, Current drug metabolism.

[5]  P. Lønning,et al.  P53 and its molecular basis to chemoresistance in breast cancer , 2012, Expert opinion on therapeutic targets.

[6]  V. Adam,et al.  Insight to physiology and pathology of zinc(II) ions and their actions in breast and prostate carcinoma. , 2011, Current medicinal chemistry.

[7]  P. Barbry,et al.  CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  M. Chatterjee,et al.  A Review of Metallothionein Isoforms and their Role in Pathophysiology , 2011, World journal of surgical oncology.

[9]  M. Nagata,et al.  Role of zinc in cellular zinc trafficking and mineralization in a murine osteoblast-like cell line. , 2011, The Journal of nutritional biochemistry.

[10]  V. Adam,et al.  Serum metallothionein in newly diagnosed patients with childhood solid tumours. , 2010, Acta biochimica Polonica.

[11]  I. Kwun,et al.  Zinc may increase bone formation through stimulating cell proliferation, alkaline phosphatase activity and collagen synthesis in osteoblastic MC3T3-E1 cells , 2010, Nutrition research and practice.

[12]  S. Sommerville,et al.  Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone , 2010, British Journal of Cancer.

[13]  D. Breljak,et al.  Role of metallothionein in cadmium traffic and toxicity in kidneys and other mammalian organs , 2010, BioMetals.

[14]  M. Yamaguchi.  Role of nutritional zinc in the prevention of osteoporosis , 2010, Molecular and Cellular Biochemistry.

[15]  Jianxiu Wang,et al.  Studies of interaction of tumor suppressor p53 with apo-MT using surface plasmon resonance , 2009, Analytical and bioanalytical chemistry.

[16]  A. Patiño-García,et al.  Profiling of Chemonaive Osteosarcoma and Paired-Normal Cells Identifies EBF2 as a Mediator of Osteoprotegerin Inhibition to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis , 2009, Clinical Cancer Research.

[17]  Vojtech Adam,et al.  Metallothioneins and cancer. , 2009, Current protein & peptide science.

[18]  P. Tan,et al.  Over‐expression of metallothionein predicts chemoresistance in breast cancer , 2009, The Journal of pathology.

[19]  M. Knipp.  Metallothioneins and platinum(II) anti-tumor compounds. , 2009, Current medicinal chemistry.

[20]  O. Fromigué,et al.  Blockade of the RhoA-JNK-c-Jun-MMP2 Cascade by Atorvastatin Reduces Osteosarcoma Cell Invasion* , 2008, Journal of Biological Chemistry.

[21]  R. Schüle,et al.  FHL2 mediates dexamethasone‐induced mesenchymal cell differentiation into osteoblasts by activating Wnt/β‐catenin signaling‐dependent Runx2 expression , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  O. Fromigué,et al.  Statin-Induced Inhibition of 3-Hydroxy-3-Methyl Glutaryl Coenzyme A Reductase Sensitizes Human Osteosarcoma Cells to Anticancer Drugs , 2008, Journal of Pharmacology and Experimental Therapeutics.

[23]  M. Silvestrini,et al.  Modulation of genes involved in zinc homeostasis in old low-grade atherosclerotic patients under effects of HMG-CoA reductase inhibitors. , 2008, Rejuvenation research.

[24]  R. Franklin,et al.  Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues , 2008, Molecular Cancer.

[25]  L. Hightower,et al.  Heavy Metal Ions in Normal Physiology, Toxic Stress, and Cytoprotection , 2007, Annals of the New York Academy of Sciences.

[26]  M. Dietel,et al.  Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome , 2007, Virchows Archiv.

[27]  Sean Jiang,et al.  Interaction of metallothionein with tumor suppressor p53 protein , 2006, FEBS letters.

[28]  P. Auberger,et al.  RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation , 2006, Cell Death and Differentiation.

[29]  G. Ferns,et al.  Effect of statin therapy on serum trace element status in dyslipidaemic subjects. , 2005, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[30]  H. Ohgushi,et al.  Role of metallothionein isoforms in bone formation processes in rat marrow mesenchymal stem cells in culture , 2005, Biological Trace Element Research.

[31]  Z. Lee,et al.  Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein , 2004, Cancer Cell International.

[32]  M. Yılmaz,et al.  Effects of statins on oxidative stress , 2004, Biological Trace Element Research.

[33]  B. Dörken,et al.  Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy , 2003, Cell Death and Differentiation.

[34]  T. Masumizu,et al.  Growth Inhibitory Factor Prevents Neurite Extension and the Death of Cortical Neurons Caused by High Oxygen Exposure through Hydroxyl Radical Scavenging* , 2002, The Journal of Biological Chemistry.

[35]  Geng-Wen Huang,et al.  Metallothionein expression in hepatocellular carcinoma. , 2002, World journal of gastroenterology.

[36]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[37]  M. Volm,et al.  Protein expression profiles indicative for drug resistance of non-small cell lung cancer , 2002, British Journal of Cancer.

[38]  P. Coyle,et al.  Metallothionein: the multipurpose protein , 2002, Cellular and Molecular Life Sciences CMLS.

[39]  M. Tatematsu,et al.  Decreases of Metallothionein and Aminopeptidase N in Renal Cancer Tissues1 , 2001, Journal of biochemistry.

[40]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[41]  O. Fromigué,et al.  Bisphosphonates Induce Breast Cancer Cell Death In Vitro , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[42]  P. Hainaut,et al.  Metal ions as regulators of the conformation and function of the tumour suppressor protein p53: implications for carcinogenesis , 1999, Proceedings of the Nutrition Society.

[43]  C. Archer,et al.  P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma. , 1998, British Journal of Cancer.

[44]  A. Abdel-Mageed,et al.  Activation of nuclear factor kappaB: potential role in metallothionein-mediated mitogenic response. , 1998, Cancer research.

[45]  W. Maret,et al.  Thiolate ligands in metallothionein confer redox activity on zinc clusters. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  W. Maret,et al.  The glutathione redox couple modulates zinc transfer from metallothionein to zinc-depleted sorbitol dehydrogenase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  W. Maret,et al.  Control of zinc transfer between thionein, metallothionein, and zinc proteins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  M. Aschner.  The functional significance of brain metallothioneins , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  S. Lippard,et al.  Cisplatin and DNA repair in cancer chemotherapy. , 1995, Trends in biochemical sciences.

[50]  R. Palmiter,et al.  Bioactivity of metallothionein-3 correlates with its novel beta domain sequence rather than metal binding properties. , 1995, Biochemistry.

[51]  N. Saijo,et al.  Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. , 1991, Cancer research.

[52]  D. Hamer,et al.  Overexpression of metallothionein confers resistance to anticancer drugs. , 1988, Science.

[53]  M. Webber,et al.  Metallothionein induction and deinduction in human prostatic carcinoma cells: relationship with resistance and sensitivity to adriamycin. , 1988, Cancer research.

[54]  Jianxiu Wang,et al.  Interaction of tumor suppressor p53 with DNA and proteins. , 2010, Current pharmaceutical biotechnology.

[55]  D. Laukens,et al.  Human metallothionein expression under normal and pathological conditions: mechanisms of gene regulation based on in silico promoter analysis. , 2009, Critical reviews in eukaryotic gene expression.

[56]  K. Mishima,et al.  Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma. , 2003, Anticancer research.

[57]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[58]  M. Hanefeld,et al.  Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals , 1997, European Journal of Clinical Pharmacology.

[59]  G. Rosen,et al.  Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. , 1977, Archives of pathology & laboratory medicine.